BRAF-mutated melanoma, the role of encorafenib + binimetinib

Intervista a Reinhard Dummer By 5 Dicembre 2025No Comments
Dai congressi

What is the mechanism of action of the combination encorafenib + binimetinib, and what are the most recent and important clinical data in BRAF-mutated melanoma? We asked Reinhard Dummer (Senior Consultant, Dermatologische Klinik Universitäts Spital Zürich – USZ), that we met at Melanoma Bridge 2025 congress in Naples.